Cryoport (CYRX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 6, 2025, with virtual attendance available for shareholders.
Shareholders are encouraged to review proxy materials and vote by June 5, 2025.
Voting matters and shareholder proposals
Election of six directors is up for shareholder vote, with all nominees recommended by the board.
Ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2025.
Advisory vote on executive compensation for named executive officers.
Advisory vote on the preferred frequency of future say-on-pay votes, with “Year” recommended.
Other business may be transacted as properly brought before the meeting.
Board of directors and corporate governance
Six director nominees listed: Linda Baddour, Daniel Hancock, Robert Hariri, Ram M. Jagannath, Ramkumar Mandalam, and Jerrell W. Shelton.
Latest events from Cryoport
- Global C> supply chain leader with 17 commercial therapies, $56.7M Q3 revenue, and rapid sector growth.CYRX
Investor presentation30 Jun 2026 - All management proposals passed, including director elections and equity plan amendment.CYRX
AGM 20265 Jun 2026 - 16% revenue growth and 70% CGT trial share highlight strong momentum and global expansion.CYRX
Corporate presentation3 Jun 2026 - FY2025 revenue rose 12% to $176.2M, with margin expansion and strong CGT market growth.CYRX
Q4 202512 May 2026 - Q1 2026 revenue up 16–16.5%, guidance raised, and profitability expected in H2 2026.CYRX
Q1 20265 May 2026 - Strong revenue growth, digital transformation, and key governance votes mark this year's proxy.CYRX
Proxy filing23 Apr 2026 - Key votes include director elections, auditor ratification, and equity plan share increase.CYRX
Proxy filing23 Apr 2026 - Q3 2024 saw service growth, margin gains, and reaffirmed guidance despite product softness.CYRX
Q3 202414 Mar 2026 - Q2 2024 revenue hit $57.6M, with 51% cell/gene therapy growth and a $63.8M impairment loss.CYRX
Q2 202414 Mar 2026 - 2024 revenue hit $228.4M, Q4 margin rose to 45.8%, and 2025 guidance is $240–$250M with EBITDA positivity.CYRX
Q4 202414 Mar 2026